Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Cure of multiple myeloma – more hype, less reality

Bone Marrow Transplantation volume 37, pages 1–18 (2006)Cite this article

Abstract

Randomized studies have firmly established the role of autologous transplant as initial therapy in multiple myeloma (MM). Indeed, MM has emerged as the commonest indication for autologous SCT in North America. The conceptual basis for high-dose therapy is the goal of complete remission (CR) through steep reduction in tumor burden affected by single and tandem transplants. Careful analysis of the data challenges the notion of CR as a surrogate to success. Intrinsically aggressive MM, defined by known unfavorable biologic risk factors, overrides the benefit of CR. In contrast, subgroups of patients with favorable biological risk factors may achieve prolonged survival, often without ever achieving CR. Unfortunately, even with tandem transplants, there is no plateau in survival curves. To this end, sequential autologous followed by nonmyeloablative allotransplants are a novel attempt at ‘curing’ myeloma, but the results thus far have failed to show a definite plateau in survival. Given the improvements in supportive care and concomitant reduction in transplant-related mortality, conventional myeloablative allogeneic transplants need to be re-examined as an option in high-risk aggressive myeloma. At the same time, novel antimyeloma therapies, newer risk stratification and staging tools are transforming the treatment algorithm. We examine the changing role of transplantation in myeloma in the context of novel drug therapy, biologic risk stratification and improving supportive care while arguing that the current ‘one size fits all’ transplant approaches are far from a cure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L et al (eds). SEER Cancer Statistics Review, 1975–2002. National Cancer Institute: Bethesda, MD, 2002.

    Google Scholar 

  2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  4. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  5. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.

    CAS  PubMed  Google Scholar 

  6. Gianni AM, Tarella C, Bregni M, Siena S, Lombardi F, Gandola L et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994; 12: 503–509.

    CAS  PubMed  Google Scholar 

  7. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  8. Imrie K, Esmail R, Meyer RM . The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 2002; 136: 619–629.

    PubMed  Google Scholar 

  9. Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, Brozeit G et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 2003; 9: 4–37.

    PubMed  Google Scholar 

  10. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A et al. Predicting long-term (> or =5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211–217.

    PubMed  Google Scholar 

  11. McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.

    CAS  PubMed  Google Scholar 

  12. Fermand JP, Ravaud P, Katsahian S, Divine M, Leblond V, Belanger C et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age [abstract]. Blood 1999; 94 (Suppl 1): 396a (abstract 1754).

    Google Scholar 

  13. Blade J, Sureda A, Ribera J, Diaz-Mediavilla J, Garcia-Larana J, Palomera J et al. High-dose therapy/autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from Pethema after a median follow-up of 66 months. Blood 2001; 98: 815a (abstract 137).

    Google Scholar 

  14. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057.

    CAS  PubMed  Google Scholar 

  15. Crowley J, Fonseca R, Greipp P, McCoy J, Barlogie B . Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using melphalan 140 mg/m2+TBI 12 Gy (MEL+TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of Intergroup trial S9321 in the context of IFM 90 and MRC VII trials. Blood 2004; 104: 539 (ASH Annual Meeting Abstracts).

    Google Scholar 

  16. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144–2151.

    CAS  PubMed  Google Scholar 

  17. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  PubMed  Google Scholar 

  18. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  19. Fassas AB, Van Rhee F, Tricot G . Predicting long-term survival in multiple myeloma patients following autotransplants. Leuk Lymphoma 2003; 44: 749–758.

    CAS  PubMed  Google Scholar 

  20. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979–983.

    CAS  PubMed  Google Scholar 

  21. Tricot G, Reiner M, Sawyer J, Crowley J, Barlogie B . A complete remission (CR) is not a prerequisite for prolonged survival after autotransplants for multiple myeloma. Blood 2004; 104: 926 (ASH Annual Meeting Abstracts).

    Google Scholar 

  22. Fassas A, Barlogie B, Rasmussen E, Milner T, Terry J, Zangari M et al. Low incidence of complete remission but comparable event-free survival (EFS) and overall survival (OS) with a history of prior monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM) among patients receiving Total Therapy 2 (TT 2). Blood 2004; 104: 932 (ASH Annual Meeting Abstracts).

    Google Scholar 

  23. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    CAS  PubMed  Google Scholar 

  24. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927–1929.

    CAS  PubMed  Google Scholar 

  25. Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112: 814–819.

    CAS  PubMed  Google Scholar 

  26. Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438–446.

    CAS  PubMed  Google Scholar 

  27. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S . Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229–234.

    CAS  PubMed  Google Scholar 

  28. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J . Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673–679.

    CAS  PubMed  Google Scholar 

  29. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161–167.

    CAS  PubMed  Google Scholar 

  30. Tricot G, Crowley J, Stover J, Milner T, Fassas A, Zangari M et al. Lack of prognostic implications of induction response to Total Therapy 2 (TT-2) in newly diagnosed patients with multiple myeloma (MM) for post-transplant event-free survival (EFS) and overall survival (OS). Blood 2004; 104: 936 (ASH Annual Meeting Abstracts).

    Google Scholar 

  31. Fassas A, Shaughnessy J, Barlogie B . Cure of myeloma: hype or reality? Bone Marrow Transplant 2005; 35: 215–224.

    CAS  PubMed  Google Scholar 

  32. Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone Marrow Transplant 2002; 30: 479–484.

    CAS  PubMed  Google Scholar 

  33. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau J-L et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.

    CAS  PubMed  Google Scholar 

  34. Gertz M, Lacy M, Dispenzieri A, Greipp P, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14) (q13;q32), t(4;14)(p16.3;q32) and −17p13 (p53) deletions in myeloma patients treated with high dose therapy. Blood 2004; 104: 334 (ASH Annual Meeting Abstracts).

    Google Scholar 

  35. Durie BG, Jacobson J, Barlogie B, Crowley J . Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004; 22: 1857–1863.

    PubMed  Google Scholar 

  36. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558.

    CAS  PubMed  Google Scholar 

  37. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    PubMed  Google Scholar 

  38. Dewald GW, Kyle RA, Hicks GA, Greipp PR . The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380–390.

    CAS  PubMed  Google Scholar 

  39. Sawyer JR, Waldron JA, Jagannath S, Barlogie B . Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41–49.

    CAS  PubMed  Google Scholar 

  40. Smadja NV, Louvet C, Isnard F et al. Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. Br J Haematol 1995; 90: 619–624.

    CAS  PubMed  Google Scholar 

  41. Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18: 804–812.

    CAS  PubMed  Google Scholar 

  42. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925–1930.

    CAS  PubMed  Google Scholar 

  43. Juneau AL, Kaehler M, Christensen ER, Schad CR, Zinsmeister AR, Lust J et al. Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. Cancer Genet Cytogenet 1998; 103: 117–123.

    CAS  PubMed  Google Scholar 

  44. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571.

    CAS  PubMed  Google Scholar 

  45. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002; 62: 715–720.

    CAS  PubMed  Google Scholar 

  46. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

    CAS  PubMed  Google Scholar 

  47. Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Raymakers R, Verhoef G et al. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study HOVON 24 MM. Blood 2004; 104: 948 (ASH Annual Meeting Abstracts).

    Google Scholar 

  48. Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056–4061.

    PubMed  Google Scholar 

  49. Kuehl WM, Bergsagel PL . Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–187.

    CAS  PubMed  Google Scholar 

  50. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM . Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93: 13931–13936.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

    CAS  PubMed  Google Scholar 

  52. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Fonseca R, Oken MM, Greipp PR . The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001; 98: 1271–1272.

    CAS  PubMed  Google Scholar 

  54. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025–3034.

    CAS  PubMed  Google Scholar 

  55. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997; 90: 4062–4070.

    CAS  PubMed  Google Scholar 

  56. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C . Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229–2238.

    CAS  PubMed  Google Scholar 

  57. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 122: 430–440.

    PubMed  Google Scholar 

  58. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC . Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607–618.

    CAS  PubMed  Google Scholar 

  59. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659–2666.

    CAS  PubMed  Google Scholar 

  60. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and −17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    CAS  PubMed  Google Scholar 

  62. Richardson PG, Chanan-Khan A, Schlossman R, Munshi NC, Wen P, Briemberg H et al. Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM). Blood 2004; 104: 336 (ASH Annual Meeting Abstracts).

    Google Scholar 

  63. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067.

    CAS  PubMed  Google Scholar 

  64. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

    CAS  PubMed  Google Scholar 

  65. Rajkumar S, Hayman S, Lacy M, Dispenzieri A, Hoering A, Geyer S et al. Combination therapy with CC-5013 (Lenalidomide; Revlimid™) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood 2004; 104: 331 (ASH Annual Meeting Abstracts).

    Google Scholar 

  66. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Cangialosi C et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. Blood 2004; 104: 207 (ASH Annual Meeting Abstracts).

    Google Scholar 

  67. Cavenagh J, Popat R, Curry N, Stec J, Morris T, Drake M et al. PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2004; 104: 1478 (ASH Annual Meeting Abstracts).

    Google Scholar 

  68. Harousseau JL, Attal M, Leleu X, Gressin R, Hulin C, Fuzibet J-G et al. Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. Blood 2004; 104: 1490 (ASH Annual Meeting Abstracts).

    Google Scholar 

  69. Jagannath S, Durie BG, Wolf JL, Camacho E, Irwin D, Lutzky J et al. A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma. Blood 2004; 104: 333 (ASH Annual Meeting Abstracts).

    Google Scholar 

  70. Wang LM, Weber D, Delasalle K, Alexanian R . VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood 2004; 104: 210 (ASH Annual Meeting Abstracts).

    Google Scholar 

  71. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Harousseau JL et al. Melphalan–prednisone (MP), MP–thalidomide and high-dose therapy using melphalan 100 mg/m2 for newly diagnosed myeloma patients ages 65–75 years: interim analysis of the IFM 99-06 trial on 350 patients. Blood 2004; 104: 206 (ASH Annual Meeting Abstracts).

    Google Scholar 

  72. Mateos M, Blade J, Diaz M, Lahuerta JJ, Terol MJ, Hernández J et al. A phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients. Blood 2004; 10: 3462 (ASH Annual Meeting Abstracts).

    Google Scholar 

  73. Barlogie B, Hollmig K, Zangari M, Stover J, Jackson J, Milner T et al. Total Therapy 3 (TT 3) for newly diagnosed myeloma, incorporating velcade into remission induction with DT PACE: early results regarding efficacy, PBSC mobilization and toxicities. Blood 2004; 104: 538 (ASH Annual Meeting Abstracts).

    Google Scholar 

  74. Uy G, Fisher N, Devine S, Khoury HJ, Adkins D, Tomasson M et al. Bortezomib given in sequence with anthracycline and thalidomide-containing regimens does not adversely affect stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Blood 2004; 104: 541 (ASH Annual Meeting Abstracts).

    Google Scholar 

  75. Facon T, Yves Mary J, Hulin C, Benboubker L, Attal M, Harousseau J-L et al. Randomized clinical trial comparing melphalan–prednisone (MP), MP–thalidomide (MP–THAL) and high-dose therapy using melphalan 100 mg/m2 (MEL100) for newly diagnosed myeloma patients aged 65–75 years. Interim analysis of the IFM 99-06 trial on 350 patients. Blood 2004; 104: 206 (ASH Annual Meeting Abstracts).

    Google Scholar 

  76. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G . Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995; 15: 367–371.

    CAS  PubMed  Google Scholar 

  77. Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827–2833.

    CAS  PubMed  Google Scholar 

  78. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B . Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–1672.

    CAS  PubMed  Google Scholar 

  79. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  PubMed  Google Scholar 

  80. Barlogie B, Jacobson J, Sawyer J, Crowley J, Terry JA, Anaissie E et al. Increasing CR frequency as a strategy toward extending event-free survival (EFS) and overall survival (OS) in multiple myeloma (MM): 4-year results of Total Therapy II (TT II) versus Total Therapy I (TT I). Blood 2003; 102: 136 (ASH Annual Meeting Abstracts).

    Google Scholar 

  81. Barlogie B, Rasmussen T, Shaughnessy J, Anaissie E, Fassas A, Talamo G et al. Total therapy for newly diagnosed myeloma: the Arkansas experience with 1000 patients treated with Total therapy 1, 2 and 3. Haematol/Hematol J 2005; 90: p19 PL 4.04.

    Google Scholar 

  82. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    CAS  PubMed  Google Scholar 

  83. Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockevit AJ, Verhoef GEG et al. Intensive versus double intensive therapy in untreated multiple myeloma: update analysis of the randomized phase III HOVON 24 study. Haematol/Hematol J 2005; 90: 37 PL 8.01.

    Google Scholar 

  84. Goldschmidt H . Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 Trial. Haematologica 2005; 90: 38 PL 8.02.

    Google Scholar 

  85. Fermand JP . High dose therapy supported with autologous blood stem cell transplantation multiple myeloma: long term follow up of the prospective studies of the MAG group. Haematol/Hematol J 2005; 90: 40 PL 8.05.

    Google Scholar 

  86. Fermand JP, Alberti C, Marolleau JP . Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (abstract). Hematol J 2003; 4: S59.

    Google Scholar 

  87. Cavo M, Cellini C, Zamagni E . Update on high dose therapy – Italian studies. Haematologica 2005; 90: 39 (abstract PL8.04).

    Google Scholar 

  88. Cavo M, Zamagni E, Cellini C, Tosi P, Ronconi S, Cangini D et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience. Proceedings of the IXth Myeloma Workshop. Hematol J 2003; 4 (suppl.1): S60 (abstract).

    Google Scholar 

  89. Moreau P, Garban F, Facon T, Hulin C, Attal M, Benboubker L et al. Preliminary results of the IFM9903 and IFM9904 protocols comparing autologous followed by miniallogeneic transplantation and double autologous transplant in high-risk de novo multiple myeloma. Blood 2003; 102: 138 (ASH Annual Meeting Abstracts).

    Google Scholar 

  90. Attal M, Harousseau JL, Leyvraz S, Doyen C, Houlin C, Benboubker L et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02). Blood 2004; 104: 535 (ASH Annual Meeting Abstracts).

    Google Scholar 

  91. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B . Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7–11.

    CAS  PubMed  Google Scholar 

  92. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887–892.

    CAS  PubMed  Google Scholar 

  93. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Sankpal S et al. Second high-dose melphalan autograft for myeloma in patients relapsing after one autograft: Results equivalent to tandem transplantation. Bone Marrow Transplant 2002; 29 (Suppl 2): S12 (abstract 121).

    Google Scholar 

  94. Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004; 22: 1674–1681.

    CAS  PubMed  Google Scholar 

  95. Moreau P, Misbahi R, Milpied N, Morineau N, Mahe B, Vigier M et al. Long-term results (10 years) of high dose therapy in 127 patients with de novo multiple myeloma. Leukemia 2002; 16: 1838–1843.

    CAS  PubMed  Google Scholar 

  96. Gahrton G, Tura S, Flesch M, Gratwohl A, Gravett P, Lindeberg A et al. Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry. Hematol Oncol 1988; 6: 181–186.

    CAS  PubMed  Google Scholar 

  97. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267–1273.

    CAS  PubMed  Google Scholar 

  98. Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002; 30: 873–878.

    PubMed  Google Scholar 

  99. Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355–357.

    CAS  PubMed  Google Scholar 

  100. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000; 85: 930–934.

    CAS  PubMed  Google Scholar 

  101. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.

    CAS  PubMed  Google Scholar 

  102. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031–3037.

    CAS  PubMed  Google Scholar 

  103. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179–1184.

    CAS  PubMed  Google Scholar 

  104. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362–4364.

    CAS  PubMed  Google Scholar 

  105. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–4718.

    CAS  PubMed  Google Scholar 

  106. Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003; 32: 1145–1151.

    CAS  PubMed  Google Scholar 

  107. Barlogie B, Kyle R, Anderson K, Greipp P, Lazarus HM, Jacobson J et al. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2+TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup Trial S9321. Blood 2003; 102: 135 (ASH Annual Meeting Abstracts).

    Google Scholar 

  108. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322.

    CAS  PubMed  Google Scholar 

  109. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793.

    CAS  PubMed  Google Scholar 

  110. Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Bjorkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    CAS  PubMed  Google Scholar 

  111. Storb R . From myeloablative to nonmyeloablative conditioning regimens in multiple myeloma. In: Boccadero M, Pileri A (eds). Multiple Myeloma 2004. Turin, Italy, 2004, p 148.

    Google Scholar 

  112. Tricot G . Allogeneic transplantation. In: Boccadero M, Pileri A (eds). Multiple Myeloma 2004. Turin, Italy, 2004, p 143.

    Google Scholar 

  113. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411–418.

    PubMed  Google Scholar 

  114. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367–373.

    CAS  PubMed  Google Scholar 

  115. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood 2005; 105: 4532–4539.

    CAS  PubMed  Google Scholar 

  116. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.

    CAS  PubMed  Google Scholar 

  117. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924.

    CAS  PubMed  Google Scholar 

  118. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.

    CAS  PubMed  Google Scholar 

  119. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003; 31: 73–80.

    PubMed  Google Scholar 

  120. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295–1303.

    PubMed  Google Scholar 

  121. Perez-Simon JA, Martino R, Alegre A, Tomas JF, De Leon A et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–108.

    PubMed  Google Scholar 

  122. Peggs K, Mackinnon S . Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion? Leukemia 2004; 18: 1541–1542; author reply 1542–1543.

    CAS  PubMed  Google Scholar 

  123. Lokhorst H, Mutis T, Bloem AC, Verdonck LF . Strategies to improve the graft-versus-myeloma effect of allogeneic stem cell transplantation and donor lymphocyte infusions in multiple myeloma. Haematologica 2005; 90: 49 PL 9.04.

    Google Scholar 

  124. Kroger N, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Fauser A et al. Current status and perspectives of dose reduced conditioning followed by related and unrelated stem cell transplantation in patients with multiple myeloma. Haematol/Hematol J 2005; 90: 47 (abstract PL9.02).

    Google Scholar 

  125. Arora M, McGlave PB, Burns LJ, Miller JS, Barke JN, Defor TE et al. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 2005; 35: 1133–1140.

    CAS  PubMed  Google Scholar 

  126. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495–502.

    CAS  PubMed  Google Scholar 

  127. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: 511–515.

    CAS  PubMed  Google Scholar 

  128. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168.

    CAS  PubMed  Google Scholar 

  129. Shustik C, Belch A, Robinson J, Rubin S, Dolan M, Kovacs M et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2004; 2004: 14S (abstract 6510).

    Google Scholar 

  130. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myelome. Haematol/Hematol J 2005; 90: 19 PL 4.01.

    Google Scholar 

  131. Stewart AK, Chen C, Howson-Jan K, White D, Roy J, Kovacs MJ et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant. Blood 2004; 104: 335 (ASH Annual Meeting Abstracts).

    Google Scholar 

  132. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379–398.

    PubMed  Google Scholar 

  133. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    CAS  PubMed  Google Scholar 

  134. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    CAS  PubMed  Google Scholar 

  135. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33.

    PubMed  Google Scholar 

  136. Clark RE, Fraser WD . Bone turnover following autologous transplantation in multiple myeloma. Leuk Lymphoma 2002; 43: 511–516.

    PubMed  Google Scholar 

  137. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18: 1420–1426.

    CAS  PubMed  Google Scholar 

  138. Lecouvet FE, Dechambre S, Malghem J, Ferrant A, Vande Berg BC, Maldague B . Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging. AJR Am J Roentgenol 2001; 176: 91–96.

    CAS  PubMed  Google Scholar 

  139. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L . Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol 1997; 96: 103–110.

    CAS  PubMed  Google Scholar 

  140. Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC et al. Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 1998; 32: 121–127.

    CAS  PubMed  Google Scholar 

  141. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585.

    CAS  PubMed  Google Scholar 

  142. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004; 18: 1085–1092.

    CAS  PubMed  Google Scholar 

  143. Rondelli D, Re F, Bandini G, Raspadori D, Arpinati M, Senese B et al. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 1325–1331.

    CAS  PubMed  Google Scholar 

  144. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103: 1548–1556.

    CAS  PubMed  Google Scholar 

  145. Gerull S, Hegenbart U, Goerner M, Benner A, Moehler T, Goldschmidt H et al. Non-myeloablative allogeneic transplantation in patients with relapsed or refractory multiple myeloma. Blood 2004; 104: 2759 (ASH Annual Meeting Abstracts).

    Google Scholar 

  146. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574–2579.

    CAS  PubMed  Google Scholar 

  147. Bruno B, Rotta M, Omede P . Nonmyeloablative conditioning; the GITMO experience. In: Boccadero M, Pileri A (eds). Multiple Myeloma 2004. Turin, Italy, 2004, pp 144–145.

    Google Scholar 

  148. Bredeson C, Perez WS, Reece DE, Vesole DH . Non-myeloablative allogeneic transplantation (NST) as first transplant or as part of planned autologous-NST tandem transplant strategy for multiple myeloma (MM): an IBMTR study. Blood 2003; 102: 199 (ASH Annual Meeting Abstracts).

    Google Scholar 

  149. Rosinol L, Lahuerta JJ, Sureda A, de la Rubia J, Garcia-Larana JG, Hernandez J et al. Feasibility and efficacy of a planned second transplant intensification in patients with MM not achieving CR or near CR with a first autologous transplant: results from a Spanish PETHEMA/GEM study. Haematol/Hematol J 2005; 90: 50 PL9.05.

  150. Moreau P, Hulin C, Garban F, Facon T, Attal M, Benboubker L et al. Final results of the IFM 9904 protocol: double transplant±anti IL6 monoclonal antibody in high risk de novo multiple myeloma in patients less than 65 years old. Haematol/Hematol J 2005; 90: 55 (abstract PL10.05).

    Google Scholar 

  151. Bensinger W . High dose or reduced intensity conditioning for myeloma. Haematologica 2005; 90: 48 (abstract PL9.03).

    Google Scholar 

  152. Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 2003; 82: 654–659.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical College of Wisconsin, Milwaukee, WI, USA

    P Hari & M C Pasquini

  2. St Vincent's Comprehensive Cancer Center, New York, NY, USA

    D H Vesole

Authors
  1. P Hari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M C Pasquini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D H Vesole
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Hari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hari, P., Pasquini, M. & Vesole, D. Cure of multiple myeloma – more hype, less reality. Bone Marrow Transplant 37, 1–18 (2006). https://doi.org/10.1038/sj.bmt.1705194

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705194

Keywords

This article is cited by

Search

Advanced search

Quick links